This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Cardiovascular System  • Statistics and Research Methods  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: The CREATE-ECLA Trial Group reported the results of using high-dose GIK infusion in patients with acute STEMI, showing no benefit for mortality, cardiac arrest, or cardiogenic shock.¹ The DIGAMI trial reported positive outcomes of this treatment in patients with diabetes.² In DIGAMI, the investigators used a GIK infusion initially but also subsequently attempted good glycemic control with subcutaneous insulin during the initial hospital stay and after discharge. More pronounced improvement in outcomes was noted in patients who were at low risk or patients with diabetes who were previously not taking insulin. Another study of patients admitted with AMI, not previously diagnosed as having diabetes, showed that about two thirds had either abnormal glucose levels or newly diagnosed diabetes at discharge and 3 months later.³ It is reasonable to extrapolate from that study that a substantial number of patients included in the CREATE-ECLA trial, in which the . . . [Full Text of this Article]

Jayant Dey, MD
jdey@ochsner.org

Lawrence Blonde, MD; Alan Burshell, MD; Peggy Bolton, NP; Anita Richard, NP
Department of Endocrinology and Diabetes
Ochsner Clinic Foundation
New Orleans, La

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Glucose-Insulin-Potassium Infusion and Mortality in the CREATE-ECLA Trial
Carl S. Apstein
JAMA. 2005;293(21):2596-2597.
EXTRACT | FULL TEXT  

Glucose-Insulin-Potassium Infusion and Mortality in the CREATE-ECLA Trial
Leonard A. Cobb, Thomas Killip, Costas T. Lambrew, Bruce A. MacLeod, Charles E. Rackley, Harry P. Selker, and Robert J. Zalenski
JAMA. 2005;293(21):2597.
EXTRACT | FULL TEXT  

Glucose-Insulin-Potassium Infusion and Mortality in the CREATE-ECLA Trial—Reply
Shamir R. Mehta, Salim Yusuf, Rafael Diaz, and Ernesto Paolasso
JAMA. 2005;293(21):2598.
EXTRACT | FULL TEXT  

Effect of Glucose-Insulin-Potassium Infusion on Mortality in Patients With Acute ST-Segment Elevation Myocardial Infarction: The CREATE-ECLA Randomized Controlled Trial
The CREATE-ECLA Trial Group Investigators*
JAMA. 2005;293(4):437-446.
ABSTRACT | FULL TEXT